AC Immune SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AC Immune SA
Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?
Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- AC Immune, Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.